Actively Recruiting
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
Led by The Affiliated People's Hospital of Ningbo University · Updated on 2022-09-06
10
Participants Needed
1
Research Sites
245 weeks
Total Duration
On this page
Sponsors
T
The Affiliated People's Hospital of Ningbo University
Lead Sponsor
U
UTC Therapeutics Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with relapsed/refractory hematological malignancies.
CONDITIONS
Official Title
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological diagnosis of hematological malignancies (such as lymphoma, myeloma, leukemia) refractory to, or relapsing after standard therapy
- Positive expression of specific antigens
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Adequate organ functions including serum bilirubin 64 35 bcmol/L, AST/ALT < 2 times normal, serum creatinine 64 2 times upper limit of normal, and brain natriuretic peptide < 80 pg/mL
- Ability to understand the protocol, willingness to enroll, sign informed consent, and comply with study and follow-up procedures
You will not qualify if you...
- History of allergy to any drugs involved in the protocol
- History of cardiac diseases including left ventricular ejection fraction < 50% or class III/IV heart failure
- History of another malignancy tumor
- Active infections with hepatitis C, hepatitis B, HIV, or syphilis
- Any contraindications to allogeneic hematopoietic stem cell transplantation
- Uncontrolled fungal, bacterial, viral, or other infections
- Female subjects who are pregnant or lactating
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Affiliated People's Hospital of Ningbo University
Ningbo, Zhejiang, China, 315101
Actively Recruiting
Research Team
Y
Ying Lu
CONTACT
D
Dong Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here